Biophytis : 2019 Annual Financial Report made available. Read the Press Release

Press Release

Biophytis: 2019 Annual Financial Report made available

Paris, France, Cambridge (Massachusetts, United States), April 6th, 2020, - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stagebiotechnology company with a focus on the development of treatment for muscular and neuromuscular diseases, today announces the publication of the 2019 Annual Financial Report which has been filed with the Autorité des Marchés Financiers (AMF).

The Financial Report is available on Biophytis' website: http://www.biophytis.com and on AMF's

website:www.amf-france.org

***

About Biophytis

Biophytis SA is a clinically staged biotechnology company specializing in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, particularly neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne myopathy (DMD). The company intends to start MYODA clinical program in H2 2020.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward- looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website (www.biophytis.com).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

Biophytis Contact for Investor Relations Evelyne Nguyen, [e-mail]

1

Press Release

Media contact

Citigate Dewe Rogerson

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

[e-mail]

Tel: [phone]

2